| Investor | Approach | Verdict | Conviction | In one line |
|---|---|---|---|---|
| A | Quality and long-term value | Avoid | 7 | The moat is a courtroom, not a franchise |
| B | Deep value and margin of safety | Avoid | 8 | No margin of safety on contingent earnings |
| C | Global macro and reflexivity | Watch | 6 | The asymmetry arrives after the order, not before |
| D | Growth and fundamental stock picking | Buy | 7 | PAH alone can carry the price if the remedy is narrow |
One Buy of four. Liquidia needs three to enter a basket, so it does not.
Bottom line
Liquidia printed a 49.8% operating margin in its fourth consecutive quarter of rising profit, then learned this week that a Delaware court found it infringing the patent on its larger market. The number that matters is $120.8M, the committee's average probability-weighted free cash flow three years out, against the $171.5M today's market cap requires on the same clock. The judgment filings due on or about October 7, 2026 will show what each side thinks it is owed, and the order that follows collapses the range.
Key takeaways
- The economics are real and the timing is brutal. Q2 revenue was $171.68M, up 29.2% from Q1's $132.86M, at a 49.8% operating margin. On September 30, 2026, the court found two patent claims covering PH-ILD treatment valid and infringed.
- The revenue at risk cannot be measured. The PAH versus PH-ILD split is not filed, so no seat can say whether the ruling threatens a fifth of the business or half of it.
- This is not one lawsuit. Three more proceedings are live against the same adversary, including the '782 case, which asserts a patent against YUTREPIA itself.
- Cash buys time but not certainty. $284.18M of cash against $326.80M of liabilities, a royalty financing with fixed payments to 2033, and no tagged debt schedule.
- What splits the committee is the remedy, seat by seat. A refuses to price a court outcome; B prices the company off its loss-making history; C waits for the order; D buys the half that survives.
The business in 60 seconds
Liquidia sells one commercial product, YUTREPIA, an inhaled dry-powder form of treprostinil for two diseases: pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA approved it on May 23, 2025, and first shipments went out in June 2025 (Q2 2026 results release, August 12, 2026). A profit share on Sandoz's generic treprostinil injection added $1.3M in Q2. The company estimates about 45,000 treated PAH patients and more than 60,000 PH-ILD patients in the United States, so the contested indication is the larger market.
The economics are a specialty launch with almost no cost of goods: Q2 product sales of $170.4M against $10.8M of product cost, a 93.7% gross margin on our arithmetic. SG&A of $57.4M a quarter carries the sales force and the legal bills, R&D was $17.2M, and everything above falls through to operating income, which is why the margin went from -32.5% for fiscal 2025 to 49.8% in Q2.
The product is made in Morrisville, North Carolina, and its sole-source active ingredient comes from a single manufacturer in South Korea (10-K, filed March 5, 2026). L606, the next treprostinil formulation, is in a pivotal PH-ILD study.
What changed
- The ruling. The court ruled claims 1 and 14 of United Therapeutics' patent on PH-ILD treatment valid and infringed, the remaining asserted claims invalid, with proposed forms of judgment due within one week (8-K, September 30, 2026).
- The company's own remedy range. Liquidia states remedies "could range from the removal of the indication to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD) from YUTREPIA's label to a broader restriction on product availability" (8-K, September 30, 2026). It intends to file a supplement removing PH-ILD from the label and to pursue all appellate options.
- The adversary asked for more. United Therapeutics has asked the court in post-trial briefs for injunctive relief restricting YUTREPIA's availability on the market (8-K, September 30, 2026).
- The quarter before the storm. Net income of $74.7M in Q2, with cash up from $190.7M to $284.2M in six months (results release, August 12, 2026).
- A third market got a track. Fast Track for Raynaud's, an estimated 30,000 patients, with the RE-WARM study expected to begin October 2026 (8-K, September 3, 2026).
The bull case on Liquidia
The launch is working, the price already discounts a disaster, and the surviving half is bigger than the market thinks. Investor D makes the case: "The market is pricing Liquidia at an undemanding 17.0x trailing free cash flow due to panic over a Delaware patent ruling on PH-ILD, mistaking a potential indication carve-out for a complete collapse of commercial momentum." Even Investor A, whose verdict is Avoid, concedes the demand signal: "That preference is the beginning of a real commercial advantage if the legal path clears." Add unpaid optionality, Raynaud's and L606, and the bull case is a self-funding company at 17x trailing cash flow whose worst realistic outcome is a smaller, still very profitable PAH franchise.
The bear case on Liquidia
The bear case does not need to argue the company is bad, only that the earnings cannot be underwritten. Investor A: "The product shows excellent unit economics, but the main thing protecting the business is a court outcome, not a competitive advantage." Investor B goes further: five straight fiscal years of operating losses and an accumulated deficit of $498.7M leave B with tangible book of $188.37M against a $2.56B market cap. The ruling exposed the structure: one product, one molecule, one adversary, four lawsuits. The '782 case targets the product itself, and the contract case could cost Liquidia the ability to stop United Therapeutics from practicing its own methods (10-Q, August 12, 2026). A company whose diluted shares rose 41.2% from 2022 to 2025 has a funding reflex.
Valuation
What the price requires. The sheet's model starts from trailing free cash flow of $150.69M, discounted at 9.74%, growing 4.4% a year for a decade and 3% after that, reaching $171.5M in year three. A modest ask, and every seat flagged the same weakness: the starting figure was earned under a label about to change.
What the committee expects. Each seat's scenarios, weighted by their own probabilities, in millions of dollars of year-three free cash flow.
| Investor | Bear | Base | Bull | Probability-weighted, year 3 |
|---|---|---|---|---|
| A | 30%, near zero | 50%, $100M to $160M | 20%, above $300M | $125.0M |
| B | 35%, -$29.22M | 45%, $54.11M | 20%, $233.75M | $60.9M |
| C | 35%, about -$40M | 45%, about $110M | 20%, about $260M | $87.5M |
| D | 25%, -$30M | 50%, $210M | 25%, $450M | $210.0M |
| Average | $120.8M |
The average sits below the price's required path: the committee expects less cash flow than the market cap already assumes. D's bull case is the only scenario above the price's path, and the spread between B's $60.9M and D's $210.0M is the whole argument in one line.
Equity against enterprise. The trailing free cash flow yield on the market cap is 5.88%, just 0.64 points above the 10-year Treasury yield of 5.24%. Enterprise value cannot be computed because net debt is not tagged. The equity cushion is thin relative to a court's ability to delete the cash flow stream.
Our arithmetic on the mix. The filings do not disclose the PAH versus PH-ILD split, and we will not fill the gap with the equal-scripting figure circulating on a members-only forum. Q2 product sales annualize to $686.7M, and the CEO's own claim is that the inhaled category has grown almost 40% since launch with YUTREPIA taking an increasing share (results release, August 12, 2026). Whether the PAH half is $85M or $100M a quarter is what the 10-Q due November 16, 2026, should begin to expose.
Comparables
| Company | Currency | Market cap | EV | Revenue growth, last FY | Operating margin | P/E | Price / FCF | FCF yield | EV / after-tax operating income | Net debt / operating income | ROIC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Liquidia Corp (LQDA) | USD | $2.6B | n/a | 1031.2% | -32.5% | 18.5x | 17.0x | 5.9% | n/a | n/a | n/a |
| United Therapeutics Corp (UTHR) | USD | $23.2B | n/a | 10.6% | 46.9% | 17.7x | 21.3x | 4.7% | n/a | n/a | n/a |
| Mirum Pharmaceuticals, Inc. (MIRM) | USD | $5.4B | n/a | 54.7% | -4.2% | n/a | n/a | n/a | n/a | n/a | n/a |
| Sarepta Therapeutics, Inc. (SRPT) | USD | $1.9B | $1.8B | 4.3% | -37.5% | n/a | 22.6x | 4.4% | n/a | n/a | n/a |
| Ultragenyx Pharmaceutical Inc. (RARE) | USD | $1.5B | n/a | 20.2% | -79.5% | n/a | n/a | n/a | n/a | n/a | n/a |
| Ionis Pharmaceuticals Inc (IONS) | USD | $7.2B | n/a | 33.8% | -40.4% | n/a | n/a | n/a | n/a | n/a | n/a |
Source: each company's own filings and the Yahoo Finance price, computed the same way for every row. EV is market cap plus net debt. MIRM, SRPT, RARE and IONS have no P/E because trailing net income is negative; the EV, leverage and ROIC columns are n/a wherever net debt or after-tax operating income could not be sourced.
The market pays for profitability, not stories. Liquidia trades at 18.5x trailing earnings and 17.0x trailing free cash flow, against a peer set where four of five cannot be priced on earnings. The only profitable comparison is United Therapeutics, the adversary, at 17.7x earnings on a 46.9% operating margin: the market prices the two companies on the same profit engine despite the litigation between them.
Key risks
We rank by lasting damage and immediacy. Raised by tells you where each risk entered the record.
| # | Risk | Why it matters | Severity | Raised by | First signal |
|---|---|---|---|---|---|
| 1 | The remedy order | The company's own range runs from label removal to broader availability restriction, and the adversary has asked for the latter | High | 8-K, September 30, 2026; Investors A, B, C and D | The judgment filings due on or about October 7, 2026, then the order |
| 2 | The '782 case | Asserts a patent on inhaled treprostinil administration against YUTREPIA itself | High | 10-Q, August 12, 2026; Investor A; Analyst | Docket developments in filings |
| 3 | Revenue mix unknown | The PAH versus PH-ILD split is not filed, so exposed revenue cannot be sized | High | Investor B; desk arithmetic | Product revenue detail in the 10-Q due November 16, 2026 |
| 4 | Supply concentration | Sole-source treprostinil from South Korea, components from China and Taiwan, one US site | High | 10-K, filed March 5, 2026; Analyst | Risk-factor wording shifting from "may" to "has" |
| 5 | Financing obligations | Fixed royalty payments to 2033, a $15.0M minimum cash covenant, no tagged debt schedule | Medium | 10-Q, August 12, 2026; Investor B | Cash drawdown pace in the 10-Q due November 16, 2026 |
| 6 | Dilution reflex | Diluted shares rose 41.2% from 2022 to 2025; stock comp was 18.6% of revenue | Medium | Five-year history; Investor A | Diluted share count in the next filings |
| 7 | Pipeline exposure | L606's pivotal study is in PH-ILD, the indication the ruling concerns | Medium | Analyst; 8-K, September 30, 2026 | Changes to the Re-Spire design or enrollment |
| 8 | Off-label assumptions | Off-label PH-ILD prescribing after a relabel is a hypothesis; payer coverage is unknown | Medium | forum (unverified); Investor C | Filed coverage or net-sales commentary |
The filings resolve one item: the 10-K states the company has not been materially impacted by tariffs or regulatory changes to date, so the tariff component of risk 4 is prospective, not current.
What to watch
| Date | Event | What it decides |
|---|---|---|
| On or about October 7, 2026 | Proposed forms of judgment due to the Delaware court (8-K, September 30, 2026) | What remedy each side thinks it is owed |
| October 2026 | RE-WARM Phase 2a study expected to begin (8-K, September 3, 2026) | Whether the third market starts on schedule |
| By November 16, 2026 | 10-Q for the quarter to September 30, 2026, under SEC rules for a non-accelerated filer | The first quarter including the ruling; revenue, cash, legal updates |
| February 2027 | RE-WARM primary completion targeted (8-K, September 3, 2026) | The first read on the Raynaud's opportunity |
| Pending | FDA action on the supplement removing PH-ILD from the label, no filed deadline | How long YUTREPIA carries a contested label |
The committee record
| Investor | Verdict | What would change its mind |
|---|---|---|
| A | Avoid 7 | Label-only judgment plus a '782 win moves it to Watch. Revenue holding at or above half of Q2's $171.68M with margin above 35% breaks its thesis |
| B | Avoid 8 | Sustainable annual net earnings of $365.72M with restrictions resolved breaks its thesis. Tangible equity at or below zero, or cash below the $15.0M covenant, in the 10-Q due November 16, 2026, breaks its liquidity case |
| C | Watch 6 | An unstayed injunction ends the Watch toward Avoid. A surgical, stayed remedy moves it toward Buy. Q3 product sales below $120M, margin below 30%, or cash below $100M breaks the launch read |
| D | Buy 7 | A broad injunction restricting all YUTREPIA availability changes the verdict to Sell. Quarterly revenue below $85.0M or operating margin below 20.0% breaks its thesis |
Data
| Item | Figure | Source |
|---|---|---|
| Market cap | $2.56B | Price $28.64 times 89,508,891 SEC-reported shares, October 2, 2026 |
| Revenue, trailing twelve months | $450.91M | SEC EDGAR, filed periods to June 30, 2026 |
| Net income, trailing twelve months | $138.61M | SEC EDGAR, filed periods to June 30, 2026 |
| Q2 2026 revenue | $171.68M, up 1842.7% year over year | SEC EDGAR, quarter to June 30, 2026 |
| Q2 2026 operating margin | 49.8% | 10-Q segment note, filed August 12, 2026 |
| Free cash flow, trailing twelve months | $150.69M | SEC EDGAR, computed |
| Cash and equivalents | $284.18M | Balance sheet, June 30, 2026 |
| Total liabilities | $326.80M | Balance sheet, June 30, 2026 |
| Short interest | 12,377,976 shares, 13.83% of shares outstanding, 11.45 days to cover | FINRA, settlement September 15, 2026 |
| The ruling | Claims 1 and 14 valid and infringed, remaining asserted claims invalid | 8-K, September 30, 2026 |
Method. Four investors with different philosophies, each on a different AI model, read one identical fact sheet and voted independently; a name needs three Buys to enter a basket. A fifth, non-voting analyst wrote the business and risk review. The fact sheet was built from SEC filings, the ruling 8-K, and the company's results release, with forum discussion included as labelled unverified context. Every verdict is later scored under a rule we published before the first results.
As of October 3, 2026, BagsCapital manages no outside capital and holds no position in Liquidia. Nothing here is investment advice.